Top

Published in:

Open Access 01-02-2017 | Review and Perspectives

Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria

Authors: Steffen Hauptmann, Katrin Friedrich, Raymond Redline, Stefanie Avril

Published in: Virchows Archiv | Issue 2/2017

Abstract

Borderline ovarian tumors (BOT) are uncommon but not rare epithelial ovarian neoplasms, intermediate between benign and malignant categories. Since BOT were first identified >40 years ago, they have inspired controversies disproportionate to their incidence. This review discusses diagnostic criteria for the histologic subtypes of BOT, highlighting areas of diagnostic challenges, ongoing controversies, and changes in terminology implemented by the recent 2014 WHO Classification of Tumours of the Female Genital Organs. Emerging knowledge supports the notion that subtypes of borderline ovarian tumors comprise distinct biologic, pathogenetic, and molecular entities, precluding a single unifying concept for BOT. Serous borderline tumors (SBT) share molecular and genetic alterations with low-grade serous carcinomas and can present at higher stages with peritoneal implants and/or lymph node involvement, which validates their borderline malignant potential. All other (non-serous) subtypes of BOT commonly present at stage I confined to the ovary(ies) and are associated with overall survival approaching that of the general population. An important change in the WHO 2014 classification is the new terminology of non-invasive implants associated with SBT, as any invasive foci (previously called “invasive implants”) are now in line with their biological behavior considered peritoneal low-grade serous carcinoma (LGSC). The controversy regarding the terminology of non-serous borderline tumors, called by some pathologists “atypical proliferative tumor” in view of their largely benign behavior, has not been resolved. The concepts of intraepithelial carcinoma and microinvasion may evolve in further studies, as their presence appears to have no prognostic impact and is subject to considerable inter-observer variability.

Silverberg SG, Bell DA, Kurman RJ, Seidman JD, Prat J, Ronnett BM et al (2004) Borderline ovarian tumors: key points and workshop summary. Hum Pathol 35(8):910–917PubMedCrossRef

International Federation of Gynecology and Obstetrics F (1971) Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand 50(1):1–7CrossRef

Serov SS, Scully RE, Sobin LH (eds) (1973) Histological typing of ovarian tumors. Springer, Berlin Heidelberg New York for WHO, Geneva

Tavassoli FA, Devilee P (eds) (2003) Pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon

Kurman RJ, Carcangiu ML, Herrington CS, Young RHE (eds) (2014) WHO classification of tumours of female reproductive organs. Lyon, IARC

Seidman JD, Soslow RA, Vang R, Berman JJ, Stoler MH, Sherman ME et al (2004) Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Hum Pathol 35(8):918–933PubMedCrossRef

Seidman JD, Kurman RJ (2000) Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 31(5):539–557PubMedCrossRef

Gershenson DM (2002) Clinical management potential tumours of low malignancy. Best Pract Res Clin Obstet Gynaecol 16(4):513–527PubMedCrossRef

Sherman ME, Mink PJ, Curtis R, Cote TR, Brooks S, Hartge P et al (2004) Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer 100(5):1045–1052PubMedCrossRef

10.

Tinelli R, Tinelli A, Tinelli FG, Cicinelli E, Malvasi A (2006) Conservative surgery for borderline ovarian tumors: a review. Gynecol Oncol 100(1):185–191PubMedCrossRef

11.

Cadron I, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I (2007) Management of borderline ovarian neoplasms. J Clin Oncol 25(20):2928–2937PubMedCrossRef

12.

Morice P, Camatte S, Rey A, Atallah D, Lhomme C, Pautier P et al (2003) Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol 14(4):592–598PubMedCrossRef

13.

Trope C, Kaern J, Vergote IB, Kristensen G, Abeler V (1993) Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. Gynecol Oncol 51(2):236–243PubMedCrossRef

14.

Shih Ie M, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164(5):1511–1518PubMedCrossRef

15.

Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF et al (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29(2):218–224PubMedCrossRef

16.

Kurman RJ, Shih IM (2008) Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 27(2):151–160PubMedPubMedCentral

17.

Kurman RJ, Shih IM (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34(3):433–443PubMedPubMedCentralCrossRef

18.

Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM et al (2004) Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28(4):496–504PubMedCrossRef

19.

Auner V, Kriegshauser G, Tong D, Horvat R, Reinthaller A, Mustea A et al (2009) KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer 9:111PubMedPubMedCentralCrossRef

20.

Mok SC, Bell DA, Knapp RC, Fishbaugh PM, Welch WR, Muto MG et al (1993) Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 53(7):1489–1492PubMed

21.

Singer G, Oldt R 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ et al (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95(6):484–486PubMedCrossRef

22.

Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-Pearson DL et al (1993) Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 85(18):1513–1519PubMedCrossRef

23.

Laury AR, Ning G, Quick CM, Bijron J, Parast MM, Betensky RA et al (2011) Fallopian tube correlates of ovarian serous borderline tumors. Am J Surg Pathol 35(12):1759–1765PubMedPubMedCentralCrossRef

24.

Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR (2005) Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol 29(6):707–723PubMedCrossRef

25.

Bell DA, Longacre TA, Prat J, Kohn EC, Soslow RA, Ellenson LH et al (2004) Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Hum Pathol 35(8):934–948PubMedCrossRef

26.

Barcena C, Oliva E (2011) WT1 expression in the female genital tract. Adv Anat Pathol 18(6):454–465PubMedCrossRef

27.

Escobar J, Klimowicz AC, Dean M, Chu P, Nation JG, Nelson GS et al (2013) Quantification of ER/PR expression in ovarian low-grade serous carcinoma. Gynecol Oncol 128(2):371–376PubMedCrossRef

28.

Laury AR, Hornick JL, Perets R, Krane JF, Corson J, Drapkin R et al (2010) PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol 34(5):627–635PubMed

29.

Avril S, Hahn E, Specht K, Hauptmann S, Hoss C, Kiechle M et al (2012) Histopathologic features of ovarian borderline tumors are not predictive of clinical outcome. Gynecol Oncol 127(3):516–524PubMedCrossRef

30.

du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C et al (2013) Borderline tumours of the ovary: a cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) Study Group. Eur J Cancer 49(8):1905–1914PubMedCrossRef

31.

Tavassoli FA (1988) Serous tumor of low malignant potential with early stromal invasion (serous LMP with microinvasion). Mod Pathol 1(6):407–414PubMed

32.

Bell DA, Scully RE (1990) Ovarian serous borderline tumors with stromal microinvasion: a report of 21 cases. Hum Pathol 21(4):397–403PubMedCrossRef

33.

Maniar KP, Wang Y, Visvanathan K, Shih Ie M, Kurman RJ (2014) Evaluation of microinvasion and lymph node involvement in ovarian serous borderline/atypical proliferative serous tumors: a morphologic and immunohistochemical analysis of 37 cases. Am J Surg Pathol 38(6):743–755PubMedPubMedCentralCrossRef

34.

McKenney JK, Balzer BL, Longacre TA (2006) Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion. Am J Surg Pathol 30(10):1209–1221PubMedCrossRef

35.

Silva EG, Deavers MT, Malpica A (2010) Patterns of low-grade serous carcinoma with emphasis on the nonepithelial-lined spaces pattern of invasion and the disorganized orphan papillae. Int J Gynecol Pathol 29(6):507–512PubMedCrossRef

36.

Du Bois A, Ewald-Riegler N, Du Bois O, Harter P (2009) Borderlinetumoren des Ovars—eine systematische Übersicht. Borderline tumors of the ovary—a systematic review. Geburtshilfe Frauenheilkd 69:1–27 GermanCrossRef

37.

Prat J, De Nictolis M (2002) Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol 26(9):1111–1128PubMedCrossRef

38.

Ronnett BM, Kajdacsy-Balla A, Gilks CB, Merino MJ, Silva E, Werness BA et al (2004) Mucinous borderline ovarian tumors: points of general agreement and persistent controversies regarding nomenclature, diagnostic criteria, and behavior. Hum Pathol 35(8):949–960PubMedCrossRef

39.

Burks RT, Sherman ME, Kurman RJ (1996) Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol 20(11):1319–1330PubMedCrossRef

40.

Seidman JD, Kurman RJ (1996) Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 20(11):1331–1345PubMedCrossRef

41.

May T, Virtanen C, Sharma M, Milea A, Begley H, Rosen B et al (2010) Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary. Gynecol Oncol 117(1):9–17PubMedCrossRef

42.

Dodson MK, Hartmann LC, Cliby WA, DeLacey KA, Keeney GL, Ritland SR et al (1993) Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas. Cancer Res 53(19):4456–4460PubMed

43.

Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M et al (2005) Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24(6):1053–1065PubMedCrossRef

44.

Hauptmann S, Denkert C, Koch I, Petersen S, Schluns K, Reles A et al (2002) Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization. Hum Pathol 33(6):632–641PubMedCrossRef

45.

Diebold J, Deisenhofer I, Baretton GB, Blasenbreu S, Suchy B, Schneiderbanger K et al (1996) Interphase cytogenetic analysis of serous ovarian tumors of low malignant potential: comparison with serous cystadenomas and invasive serous carcinomas. Lab Investig 75(4):473–485PubMed

46.

Osterberg L, Akeson M, Levan K, Partheen K, Zetterqvist BM, Brannstrom M et al (2006) Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas. Cancer Genet Cytogenet 167(2):103–108PubMedCrossRef

47.

Staebler A, Heselmeyer-Haddad K, Bell K, Riopel M, Perlman E, Ried T et al (2002) Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas. Hum Pathol 33(1):47–59PubMedCrossRef

48.

Park JY, Kim DY, Kim JH, Kim YM, Kim KR, Kim YT et al (2011) Micropapillary pattern in serous borderline ovarian tumors: does it matter? Gynecol Oncol 123(3):511–516PubMedCrossRef

49.

Eichhorn JH, Bell DA, Young RH, Scully RE (1999) Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns. Am J Surg Pathol 23(4):397–409PubMedCrossRef

50.

Hannibal CG, Vang R, Junge J, Frederiksen K, Kjaerbye-Thygesen A, Andersen KK et al (2014) A nationwide study of serous “borderline” ovarian tumors in Denmark 1978-2002: centralized pathology review and overall survival compared with the general population. Gynecol Oncol 134(2):267–273PubMedPubMedCentralCrossRef

51.

Deavers MT, Gershenson DM, Tortolero-Luna G, Malpica A, Lu KH, Silva EG (2002) Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases. Am J Surg Pathol 26(9):1129–1141PubMedCrossRef

52.

Shih KK, Zhou Q, Huh J, Morgan JC, Iasonos A, Aghajanian C et al (2011) Risk factors for recurrence of ovarian borderline tumors. Gynecol Oncol 120(3):480–484PubMedCrossRef

53.

Segal GH, Hart WR (1992) Ovarian serous tumors of low malignant potential (serous borderline tumors). The relationship of exophytic surface tumor to peritoneal “implants”. Am J Surg Pathol 16(6):577–583PubMedCrossRef

54.

Bell KA, Smith Sehdev AE, Kurman RJ (2001) Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas. Am J Surg Pathol 25(4):419–432PubMedCrossRef

55.

Gershenson DM, Silva EG, Levy L, Burke TW, Wolf JK, Tornos C (1998) Ovarian serous borderline tumors with invasive peritoneal implants. Cancer 82(6):1096–1103PubMedCrossRef

56.

Sobin LH, Gospodarovicz MK, Wittekind C (eds) (2010) TNM classification of malignant tumours, 7th edn. Wiley, Oxford

57.

Ji H, Isacson C, Seidman JD, Kurman RJ, Ronnett BM (2002) Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol 21(4):391–400PubMedCrossRef

58.

Hart WR (2005) Mucinous tumors of the ovary: a review. Int J Gynecol Pathol 24(1):4–25PubMed

59.

Nomura K, Aizawa S (1996) Clinicopathologic and mucin histochemical analyses of 90 cases of ovarian mucinous borderline tumors of intestinal and mullerian types. Pathol Int 46(8):575–580PubMedCrossRef

60.

Vang R, Gown AM, Barry TS, Wheeler DT, Ronnett BM (2006) Ovarian atypical proliferative (borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive. Int J Gynecol Pathol 25(1):83–89PubMedCrossRef

61.

Vang R, Gown AM, Barry TS, Wheeler DT, Ronnett BM (2006) Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Mod Pathol 19(1):97–105PubMedCrossRef

62.

Vang R, Gown AM, Barry TS, Wheeler DT, Yemelyanova A, Seidman JD et al (2006) Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am J Surg Pathol 30(9):1130–1139PubMedCrossRef

63.

Vang R, Gown AM, Wu LS, Barry TS, Wheeler DT, Yemelyanova A et al (2006) Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol 19(11):1421–1428PubMed

64.

Laury AR, Perets R, Piao H, Krane JF, Barletta JA, French C et al (2011) A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol 35(6):816–826PubMedCrossRef

65.

Anglesio MS, Kommoss S, Tolcher MC, Clarke B, Galletta L, Porter H et al (2013) Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol 229(1):111–120PubMedCrossRef

66.

Uzan C, Nikpayam M, Ribassin-Majed L, Gouy S, Bendifallah S, Cortez A et al (2014) Influence of histological subtypes on the risk of an invasive recurrence in a large series of stage I borderline ovarian tumor including 191 conservative treatments. Ann Oncol 25(7):1312–1319PubMedCrossRef

67.

Ronnett BM, Seidman JD (2003) Mucinous tumors arising in ovarian mature cystic teratomas: relationship to the clinical syndrome of pseudomyxoma peritonei. Am J Surg Pathol 27(5):650–657PubMedCrossRef

68.

Seidman JD, Khedmati F (2008) Exploring the histogenesis of ovarian mucinous and transitional cell (Brenner) neoplasms and their relationship with Walthard cell nests: a study of 120 tumors. Arch Pathol Lab Med. 132(11):1753–1760PubMed

69.

Seidman JD, Yemelyanova A, Zaino RJ, Kurman RJ (2011) The fallopian tube-peritoneal junction: a potential site of carcinogenesis. Int J Gynecol Pathol 30(1):4–11PubMedCrossRef

70.

Wang Y, Wu RC, Shwartz LE, Haley L, Lin MT, Shih IM, et al. (2015) Clonality analysis of combined Brenner and mucinous tumours of the ovary reveals their monoclonal origin. J Pathol 237(2):146–51

71.

Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J (1997) K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer 79(8):1581–1586PubMedCrossRef

72.

Mackenzie R, Kommoss S, Winterhoff BJ, Kipp BR, Garcia JJ, Voss J et al (2015) Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. BMC Cancer 15:415PubMedPubMedCentralCrossRef

73.

Russell SE, McCluggage WG (2004) A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. J Pathol 203(2):617–619PubMedCrossRef

74.

Khunamornpong S, Settakorn J, Sukpan K, Suprasert P, Siriaunkgul S (2011) Mucinous tumor of low malignant potential (“borderline” or “atypical proliferative” tumor) of the ovary: a study of 171 cases with the assessment of intraepithelial carcinoma and microinvasion. Int J Gynecol Pathol 30(3):218–230PubMedCrossRef

75.

Lee KR, Scully RE (2000) Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with ‘pseudomyxoma peritonei’. Am J Surg Pathol 24(11):1447–1464PubMedCrossRef

76.

Riopel MA, Ronnett BM, Kurman RJ (1999) Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol 23(6):617–635PubMedCrossRef

77.

Kim KR, Lee HI, Lee SK, Ro JY, Robboy SJ (2007) Is stromal microinvasion in primary mucinous ovarian tumors with “mucin granuloma” true invasion? Am J Surg Pathol 31(4):546–554PubMedCrossRef

78.

Rodriguez IM, Prat J (2002) Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol 26(2):139–152PubMedCrossRef

79.

Provenza C, Young RH, Prat J (2008) Anaplastic carcinoma in mucinous ovarian tumors: a clinicopathologic study of 34 cases emphasizing the crucial impact of stage on prognosis, their histologic spectrum, and overlap with sarcomalike mural nodules. Am J Surg Pathol 32(3):383–389PubMedCrossRef

80.

Hart WR, Norris HJ (1973) Borderline and malignant mucinous tumors of the ovary. Histologic criteria and clinical behavior. Cancer 31(5):1031–1045PubMedCrossRef

81.

de Nictolis M, Montironi R, Tommasoni S, Valli M, Pisani E, Fabris G et al (1994) Benign, borderline, and well-differentiated malignant intestinal mucinous tumors of the ovary: a clinicopathologic, histochemical, immunohistochemical, and nuclear quantitative study of 57 cases. Int J Gynecol Pathol 13(1):10–21PubMedCrossRef

82.

Schiavone MB, Herzog TJ, Lewin SN, Deutsch I, Sun X, Burke WM et al (2011) Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol 205(5):480 e1–480 e8CrossRef

83.

Zaino RJ, Brady MF, Lele SM, Michael H, Greer B, Bookman MA (2011) Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study. Cancer 117(3):554–562PubMedCrossRef

84.

Lee KR, Young RH (2003) The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol 27(3):281–292PubMedCrossRef

85.

Ronnett BM, Kurman RJ, Zahn CM, Shmookler BM, Jablonski KA, Kass ME et al (1995) Pseudomyxoma peritonei in women: a clinicopathologic analysis of 30 cases with emphasis on site of origin, prognosis, and relationship to ovarian mucinous tumors of low malignant potential. Hum Pathol 26(5):509–524PubMedCrossRef

86.

Seidman JD, Kurman RJ, Ronnett BM (2003) Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 27(7):985–993PubMedCrossRef

87.

Young RH (2006) From krukenberg to today: the ever present problems posed by metastatic tumors in the ovary: part I. Historical perspective, general principles, mucinous tumors including the krukenberg tumor. Adv Anat Pathol 13(5):205–227PubMedCrossRef

88.

Young RH (2007) From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II. Adv Anat Pathol 14(3):149–177PubMedCrossRef

89.

McKenney JK, Soslow RA, Longacre TA (2008) Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei. Am J Surg Pathol 32(5):645–655PubMedCrossRef

90.

Vang R, Gown AM, Zhao C, Barry TS, Isacson C, Richardson MS et al (2007) Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary. Am J Surg Pathol 31(6):854–869PubMedCrossRef

91.

Chu PG, Schwarz RE, Lau SK, Yen Y, Weiss LM (2005) Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol 29(3):359–367PubMedCrossRef

92.

Su MC, Yuan RH, Lin CY, Jeng YM (2008) Cadherin-17 is a useful diagnostic marker for adenocarcinomas of the digestive system. Mod Pathol 21(11):1379–1386PubMedCrossRef

93.

Kaspar HG, Crum CP (2015) The utility of immunohistochemistry in the differential diagnosis of gynecologic disorders. Arch Pathol Lab Med 139(1):39–54PubMedCrossRef

94.

Groisman GM, Meir A, Sabo E (2004) The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries. Int J Gynecol Pathol 23(1):52–57PubMedCrossRef

95.

Chou YY, Jeng YM, Kao HL, Chen T, Mao TL, Lin MC (2003) Differentiation of ovarian mucinous carcinoma and metastatic colorectal adenocarcinoma by immunostaining with beta-catenin. Histopathology 43(2):151–156PubMedCrossRef

96.

Jiang Z, Fanger GR, Woda BA, Banner BF, Algate P, Dresser K et al (2003) Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: a study of 761 cases. Hum Pathol 34(8):792–796PubMedCrossRef

97.

Uzan C, Dufeu-Lefebvre M, Fauvet R, Gouy S, Duvillard P, Darai E et al (2012) Management and prognosis of borderline ovarian Brenner tumors. Int J Gynecol Cancer 22(8):1332–1336PubMedCrossRef

98.

Roma AA, Masand RP (2014) Ovarian Brenner tumors and Walthard nests: a histologic and immunohistochemical study. Hum Pathol 45(12):2417–2422PubMedCrossRef

99.

Cuatrecasas M, Catasus L, Palacios J, Prat J (2009) Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas. Am J Surg Pathol 33(4):556–567PubMedCrossRef

100.

Kuhn E, Ayhan A, Shih Ie M, Seidman JD, Kurman RJ (2014) The pathogenesis of atypical proliferative Brenner tumor: an immunohistochemical and molecular genetic analysis. Mod Pathol 27(2):231–237PubMedCrossRef

101.

Logani S, Oliva E, Amin MB, Folpe AL, Cohen C, Young RH (2003) Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications. Am J Surg Pathol 27(11):1434–1441PubMedCrossRef

102.

Roth LM, Gersell DJ, Ulbright TM (1996) Transitional cell carcinoma and other transitional cell tumors of the ovary. Anat Pathol 1:179–191PubMed

103.

Giudice LC (2010) Clinical practice. Endometriosis. N Engl J Med 362(25):2389–2398PubMedPubMedCentralCrossRef

104.

Van Langendonckt A, Luyckx M, Gonzalez MD, Defrere S, Donnez J, Squifflet J (2010) Differential expression of genes from the homeobox A cluster in deep endometriotic nodules and peritoneal lesions. Fertil Steril 94(6):1995–2000PubMedCrossRef

105.

Clement PB (2007) The pathology of endometriosis: a survey of the many faces of a common disease emphasizing diagnostic pitfalls and unusual and newly appreciated aspects. Adv Anat Pathol 14(4):241–260PubMedCrossRef

106.

Leconte M, Nicco C, Ngo C, Chereau C, Chouzenoux S, Marut W et al (2011) The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice. Am J Pathol 179(2):880–889PubMedPubMedCentralCrossRef

107.

Korner M, Burckhardt E, Mazzucchelli L (2006) Higher frequency of chromosomal aberrations in ovarian endometriosis compared to extragonadal endometriosis: a possible link to endometrioid adenocarcinoma. Mod Pathol 19(12):1615–1623PubMedCrossRef

108.

Samartzis EP, Samartzis N, Noske A, Fedier A, Caduff R, Dedes KJ et al (2012) Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation? Mod Pathol 25(6):885–892PubMedCrossRef

109.

Grechukhina O, Petracco R, Popkhadze S, Massasa E, Paranjape T, Chan E et al (2012) A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis. EMBO molecular medicine 4(3):206–217PubMedPubMedCentralCrossRef

110.

Wei JJ, William J, Bulun S (2011) Endometriosis and ovarian cancer: a review of clinical, pathologic, and molecular aspects. Int J Gynecol Pathol 30(6):553–568PubMedPubMedCentralCrossRef

111.

Kurman RJ, Shih IM (2016) Seromucinous tumors of the ovary. What’s in a name? Int J Gynecol Pathol 35(1):78–81PubMedCrossRef

112.

Taylor J, McCluggage WG (2015) Ovarian seromucinous carcinoma: report of a series of a newly categorized and uncommon neoplasm. Am J Surg Pathol 39(7):983–992PubMedCrossRef

113.

Shappell HW, Riopel MA, Smith Sehdev AE, Ronnett BM, Kurman RJ (2002) Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol 26(12):1529–1541PubMedCrossRef

114.

Rodriguez IM, Irving JA, Prat J (2004) Endocervical-like mucinous borderline tumors of the ovary: a clinicopathologic analysis of 31 cases. Am J Surg Pathol 28(10):1311–1318PubMedCrossRef

115.

Maeda D, Shih IM (2013) Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms. Adv Anat Pathol 20(1):45–52PubMedPubMedCentralCrossRef

116.

Wu CH, Mao TL, Vang R, Ayhan A, Wang TL, Kurman RJ et al (2012) Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A. Int J Gynecol Pathol 31(4):297–303PubMedPubMedCentralCrossRef

117.

Kim KR, Choi J, Hwang JE, Baik YA, Shim JY, Kim YM et al (2010) Endocervical-like (mullerian) mucinous borderline tumours of the ovary are frequently associated with the KRAS mutation. Histopathology 57(4):587–596PubMedCrossRef

118.

Yasunaga M, Ohishi Y, Oda Y, Misumi M, Iwasa A, Kurihara S et al (2009) Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors. Hum Pathol 40(7):965–974PubMedCrossRef

119.

Roth LM, Emerson RE, Ulbright TM (2003) Ovarian endometrioid tumors of low malignant potential: a clinicopathologic study of 30 cases with comparison to well-differentiated endometrioid adenocarcinoma. Am J Surg Pathol 27(9):1253–1259PubMedCrossRef

120.

Bell KA, Kurman RJ (2000) A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary. Am J Surg Pathol 24(11):1465–1479PubMedCrossRef

121.

Stewart CJ, Leung Y, Walsh MD, Walters RJ, Young JP, Buchanan DD (2012) KRAS mutations in ovarian low-grade endometrioid adenocarcinoma: association with concurrent endometriosis. Hum Pathol 43(8):1177–1183PubMedCrossRef

122.

Vang R, Gown AM, Farinola M, Barry TS, Wheeler DT, Yemelyanova A et al (2007) p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol 31(5):653–663PubMedCrossRef

123.

Uzan C, Berretta R, Rolla M, Gouy S, Fauvet R, Darai E et al (2012) Management and prognosis of endometrioid borderline tumors of the ovary. Surg Oncol 21(3):178–184PubMedCrossRef

124.

Roth LM, Langley FA, Fox H, Wheeler JE, Czernobilsky B (1984) Ovarian clear cell adenofibromatous tumors. Benign, of low malignant potential, and associated with invasive clear cell carcinoma. Cancer 53(5):1156–1163PubMedCrossRef

125.

Bell DA, Scully RE (1985) Benign and borderline clear cell adenofibromas of the ovary. Cancer 56(12):2922–2931PubMedCrossRef

126.

Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O (2012) PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. Virchows Arch 460(1):77–87PubMedCrossRef

127.

Kato N, Takeda J, Fukase M, Motoyama T (2010) Alternate mucoid and hyalinized stroma in clear cell carcinoma of the ovary: manifestation of serial stromal remodeling. Mod Pathol 23(6):881–888PubMedCrossRef

128.

Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C et al (2008) Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5(12):e232PubMedPubMedCentralCrossRef

Title: Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria
Authors: Steffen Hauptmann
Katrin Friedrich
Raymond Redline
Stefanie Avril
Publication date: 01-02-2017
Publisher: Springer Berlin Heidelberg
Published in: Virchows Archiv / Issue 2/2017
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-016-2040-8

At a glance: The STEP trials

Springer Medicine

Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2017

Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied

Value of postmortem studies in deceased neonatal and pediatric intensive care unit patients

Erratum to: Abstracts

Adhering to the 2014 WHO terminology on borderline ovarian tumors

In this issue

Thanks to you